TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03456492

Intervention type: DIAGNOSTIC_TEST
Intervention: serum sodium
Description: Serum sodium will be measured on admission, assesment of mental status by Modified Mini-Mental score and measurement of glutamate in CSF sample taken while dripling during spinal anathesia for surgical intervention.

Intervention type: DIAGNOSTIC_TEST
Intervention: serum sodium
Description: Serum sodium will be measured on admission, assesment of mental status by Modified Mini-Mental score and measurement of glutamate in CSF sample taken while dripling during spinal anathesia for surgical intervention.
Study: NCT02850796

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kg-Free
Description: Cognitive-behavioral intervention based on promoting acceptance, mindfulness and self-compassion abilities

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as Usual
Description: Standard nutritional treatment that involves dietary and physical activity support provided by the medical units Standard

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as Usual
Description: Standard nutritional treatment that involves dietary and physical activity support provided by the medical units Standard
Study: NCT02282761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITI-007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITI-007

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01664026

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based lifestyle modification
Description: Access to a web-based lifestyle modification program of 6-month duration that covers all aspects of a healthy lifestyle including physical activity, nutrition and weight maintenance.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based lifestyle modification +
Description: Access to a web-based lifestyle modification program of 6-month duration that covers all aspects of a healthy lifestyle including physical activity, nutrition and weight maintenance plus telephone counseling support by health coaches on a weekly or bi-weekly basis.
Study: NCT03820492

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: OCT, FFR, CTA and FFRCT
Description: Multimodality assessment of intermediate left main stenosis: Comparison of optical coherence tomography-derived minimal lumen area, invasive fractional flow reserve and FFRCT
Study: NCT02522819

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: Use of CPAP over 5 nights for the treatment of obstructive sleep apnea in the acute phase of stroke.
Study: NCT00460928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous immune globulin (IVIG)
Study: NCT00318955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Study: NCT02371629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVA237
Description: NVA237 capsules for inhalation, delivered via a Single Dose Dry Powder Inhaler (SDDPI) called Concept1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVA237
Description: NVA237 capsules for inhalation, delivered via a Single Dose Dry Powder Inhaler (SDDPI) called Concept1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to NVA237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol
Description: All patients received salbutamol (100 μg) as only rescue medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol
Description: All patients received salbutamol (100 μg) as only rescue medication
Study: NCT00551707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRx-102 (2.7/180)
Description: prednisolone 2.7 mg plus dipyridamole 180 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRx-102 (2.7/180)
Description: prednisolone 2.7 mg plus dipyridamole 180 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisolone
Description: prednisolone (2.7 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dipyridamole
Description: dipyridamole 360 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRx-102 (2.7/360)
Description: Prednisolone 2.7 mg plus Dipyridamole 360 mg
Study: NCT03497299

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active rTMS (20Hz)
Description: Repetitive Transcranial Magnetic Stimulation (rTMS) Procedures: On Day 1, participants will be randomly assigned to receive active or sham rTMS using the MagProX100/R30 stimulator equipped with the B65 active/ placebo coil for DLPFC stimulator (MagVenture, Farum, Denmark) for a period of 28 days.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS
Description: Repetitive Transcranial Magnetic Stimulation (rTMS) Procedures: On Day 1, participants will be randomly assigned to receive active or sham rTMS using the MagProX100/R30 stimulator equipped with the B65 active/ placebo coil for DLPFC stimulator (MagVenture, Farum, Denmark) for a period of 28 days.
Study: NCT05241587

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gum Group:
Description: Gum Group:~Gum group patients consisted of patients who chewed Xylitol Granule Filled Dragee Sugar Free Gum/Xylitol Gum/First X-Fresh. It is reported that the use of xylitol five times a day (not less than three times) is appropriate and effective (Xylitol, 2020; Xylitol, 2006; Llop, et al., 2010).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mouth Spray Group:
Description: Mouth Spray Group:~The patients in the mouth spray group included those who had been using Oral Spray/Act Dry Mouth Spray regularly as two puffs three times a day at the request of the physician for the last two weeks. This group of patients continued to use the mouth spray at the physician's request.
Study: NCT05315440

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: graston tecnique
Description: Graston technique involves the use of steel tools that are used non-invasively on the skin to identify and treat areas that have stiffness or inflammation. These areas can be located with greater precision than the manual technique precisely because the instruments do not compress in contact with the patient's skin, as is the case with the physiotherapist's fingertips. Thanks to the instruments it is therefore possible to detect the areas of altered consistency and to treat them by pressing a minimum pressure.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rehabilitation
Description: 30 minutes of passive and active assisted mobilization guided by the therapist, 30 min of Continous passive movement in flexion and abduction and 30 minutes of electrostimulation.
Study: NCT04833036

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: 180 mg/m2, ivgtt d1，q2w
Study: NCT02323061

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BCI using EEG signals
Description: A robot hand will be used and controlled by the system in real time based on EEG pattern for identification of motion intention for hand movements in the cortex.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: BCI using EEG signals
Description: A robot hand will be used and controlled by the system in real time based on EEG pattern for identification of motion intention for hand movements in the cortex.
Study: NCT01594268

Intervention type: DRUG
Group type: OTHER
Intervention: Everolimus
Description: A prospective, open-label study to assess safety of Certican in kidney transplant patients
Study: NCT03195530

Intervention type: DRUG
Intervention: Propofol
Description: Induction of anesthesia using propofol, and recording the BIS values and EEG patterns during the induction
Study: NCT03055195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepolizumab 100 mg
Description: Mepolizumab is available as lyophilized powder in sterile vials for injection. The content is reconstituted with 1.2 milliliter (mL) Sterile Water just prior to use. Subjects will receive 1mL (100 mg/mL) bolus subcutaneous injections.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching mepolizumab
Description: Placebo is available as 0.9% sodium chloride solution. Subjects will receive 1mL bolus subcutaneous injections.
Study: NCT02375997

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palliative care
Description: Early nutrition intervention and psychological intervention
Study: NCT01794975

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atomoxetine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cold pressor test

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03033043

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Relay Pro Stent-Graft
Description: Endovascular treatment of an aortic dissection
Study: NCT02952677

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remind-to-move
Description: Participants were required to wear sensory cueing wristwatch devices with vibration emitted on the affected arm for 3 consecutive hours daily, for a total of 4 weeks, at any time during the day, and received usual care as well.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Participants were required to wear sensory cueing wristwatch devices without vibration emitted on the affected arm for 3 consecutive hours daily, for a total of 4 weeks, at any time during the day, and received usual care as well.

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Participants received usual care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Participants received usual care

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Participants received usual care
Study: NCT00677287

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RNF43, TOMM34, VEGFR1 and VEGFR2
Description: Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, RNF43 peptide (1mg), TOMM34 peptide (1mg), VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection in combination with Tegafur/Uracil/Folinate chemotherapy.
Study: NCT05003999

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HPC - SpeediCath ®
Description: The investigators measure the time taken to perform intermittent catheterization using a 13 step pre-determined intermittent catheterization protocol using a hydrophilic catheter

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-HPC - Self-Cath ®
Description: The investigators measure the time taken to perform intermittent catheterization using a 13 step pre-determined intermittent catheterization protocol using a non-hydrophilic catheter; Lubrication jelly (MUKO ®, 3.5g package, Cardinal Health Canada Inc, Toronto, ON, Canada) was provided
Study: NCT02550210

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Breast Cancer Locator (BCL)
Description: This locator is constructed pre-operatively, sterilized and provided to the surgeon at the time of the procedure. The outline of the breast cancer on the breast surface at the point where the cancer is closest to the skin is built into the locator, so that the surgeon can simply apply the locator to the patient's breast and trace the tumor outline on the skin.
Study: NCT00924482

Intervention type: DEVICE
Group type: OTHER
Intervention: Placed ECOM endotracheal cardiac output monitor in patients undergoing cardiac surgery
Description: Measure cardiac output during perioperative period and compare to pulmonary artery thermodilution cardiac output measurements.
Study: NCT01027416

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: Drug: Tamoxifen 20 mg orally 1x/day for 4 weeks
Study: NCT00396669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: We measure dopamine release at the striatum using 11 C Raclopride at baseline and after smoking a cigarette

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: Brain imaging after treatment with Bupropion
Study: NCT00899275

Intervention type: OTHER
Intervention: Cytology Specimen Collection Procedure
Description: Correlative studies
Study: NCT02912377

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neulasta, B12019
Description: GCSF, Growth Colony Stimulating Factor

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neulasta, B12019
Description: GCSF, Growth Colony Stimulating Factor
Study: NCT00226733

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Interval exercise training with high intensity five days per week for four weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training
Description: Exercise training with moderate intensity, five days per week for four weeks.
Study: NCT01056575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OC000459
Description: OC000459 100mg tablet, twice daily
Study: NCT00477724

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exercise and respiratory therapy
Description: exercise and respiratory therapy for three weeks in-hospital and 15 weeks at home

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: sedentary control group
Description: control group with no specific training
Study: NCT00999206

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Vaccine
Description: surface antigen, inactivated, prepared in cell cultures

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza Vaccine
Description: surface antigen, inactivated, prepared in egg (influvac ®)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Vaccine
Description: surface antigen, inactivated, prepared in cell cultures

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Vaccine
Description: surface antigen, inactivated, prepared in cell cultures
Study: NCT00770484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol then Placebo
Description: Propanolol 20 mg, given orally within 1 hour prior to exercising

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo then Propranolol
Description: Placebo, matching pill given orally within 1 hour prior to exercising
Study: NCT03687255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cefepime/AAI101 combination
Description: cefepime 2 g / AAI101 500 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piperacillin/tazobactam
Description: piperacillin 4 GM / tazobactam 500 MG
Study: NCT02866383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 3 mg/kg is given over 60 minutes I.V. on day 1 just after radiation and then every 2 weeks (q2w)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 3 mg/kg is given over 60 minutes I.V. on day 1 just after radiation and then every 2 weeks (q2w)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: 1 mg/kg is given over 90 minutes I.V. on day 1 30 minutes after the completion of nivolumab infusion and then every 6 weeks IV (q6w)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 15 Gy x 1 fraction given on day 1

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 15 Gy x 1 fraction given on day 1
Study: NCT02909647

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative planning
Description: preoperative planning using 3D digital planning software or conventional template

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative planning
Description: preoperative planning using 3D digital planning software or conventional template

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Osteosynthesis
Description: osteosynthesis using volar locking plate

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Osteosynthesis
Description: osteosynthesis using volar locking plate
Study: NCT03083041

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: SHR-1210 will be administered as a 30-minute IV infusion Q2W at a dose of 200mg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: SHR-1210 will be administered as a 30-minute IV infusion Q2W at a dose of 200mg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: SHR-1210 will be administered as a 30-minute IV infusion Q2W at a dose of 200mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib tablet will be administered orally,once daily until progression
Study: NCT04833036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 180 mg/m2, ivgtt d1，q2w

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cetuximab
Description: 500 mg/m2, ivgtt d1，q2w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: 500 mg/m2, ivgtt d1，q2w
Study: NCT03880812

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Societal cost
Description: Annual societal cost information to the US for carpal tunnel release surgery was displayed.
Study: NCT01663649

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Deprexis
Description: web-based treatment program for depression

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Deprexis
Description: web-based treatment program for depression

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wait-list
Description: the wait-list group receives Deprexis after 6 month
Study: NCT03406962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGTA-456
Description: Hematopoietic stem cell transplantation will be done with the cell therapy product MGTA-456.
Study: NCT02704104

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AC5 Topical Hemostatic Device
Description: Randomized application of the hemostatic agent AC5 to one of two freshly excised lesions in each patient

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: AC5 Topical Hemostatic Device
Description: Randomized application of the hemostatic agent AC5 to one of two freshly excised lesions in each patient
Study: NCT00824421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UK-453, 061
Description: UK-453,061 500 mg tablets PO QD + Tenofovir DF 300 mg/Emtricitabine 200 mg tablets PO QD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UK-453, 061
Description: UK-453,061 750 mg tablets PO QD + Tenofovir DF 300 mg/Emtricitabine 200 mg tablets PO QD.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EFV +TVA
Description: Efavirenz 600 mg tablets PO QD + Tenofovir DF 300 mg/Emtricitabine 200 tablets mg PO QD.
Study: NCT00983775

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: jet injector (SQ pen/Novopen III)
Description: The rapid-acting insulin analogue insulin aspart (Novorapid®), at a dose of 0.2 units per kg body weight, will be injected subcutaneously. On one experimental day insulin will be injected with the jet injector and placebo with the conventional insulin pen. On the other experimental day insulin will be injected with the conventional insulin pen and placebo with the jet injector.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: jet injector (SQ pen/Novopen III)
Description: The rapid-acting insulin analogue insulin aspart (Novorapid®), at a dose of 0.4 units per kg body weight, will be injected subcutaneously. On one experimental day insulin will be injected with the jet injector and placebo with the conventional insulin pen. On the other experimental day insulin will be injected with the conventional insulin pen and placebo with the jet injector.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: jet injector (SQ pen/Novopen III)
Description: The rapid-acting insulin analogue insulin aspart (Novorapid®), at a dose of 0.4 units per kg body weight, will be injected subcutaneously. On one experimental day insulin will be injected with the jet injector and placebo with the conventional insulin pen. On the other experimental day insulin will be injected with the conventional insulin pen and placebo with the jet injector.
Study: NCT02499952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200mg IV every 3 weeks until progressive disease, unacceptable toxicity, or after 52 weeks of therapy.
Study: NCT04025840

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Epidural block
Description: Epidural block (with 0.375% ropivacaine) is performed during surgery. Patient-controlled epidural analgesia (with a mixture of 0.12% ropivacaine and 0.5 microgram/ml sufentanyl) is provided after surgery.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Epidural block
Description: Epidural block (with 0.375% ropivacaine) is performed during surgery. Patient-controlled epidural analgesia (with a mixture of 0.12% ropivacaine and 0.5 microgram/ml sufentanyl) is provided after surgery.
Study: NCT03083041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib tablet will be administered orally,once daily until progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib tablet will be administered orally,once daily until progression
Study: NCT00350220

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: transfusion strategy
Description: For the High Hb group; transfusions will be given to keep the Hb \>13.0 g/dl

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Hb transfusion group
Description: RBCs will not be transfused unless the Hb \< 9.0 g/dl